+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Adeno-Associated Virus Vector-Based Gene Therapy Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780638
The global adeno-associated virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031, driven by the rising prevalence of genetic disorders and the increasing investments in research and development activities. The market is projected to grow at a CAGR of 18.5% during the forecast period.

Adeno-Associated Virus Vector-Based Gene Therapy Market: Introduction

The global adeno-associated virus (AAV) vector-based gene therapy market report provides an in-depth analysis of the market and its segments. AAV is a non-pathogenic virus that is used as a delivery vehicle for therapeutic genes to treat genetic disorders. The report covers the market for AAV vector-based gene therapy and provides a detailed analysis of the market size, growth, and trends.

The AAV vector-based gene therapy market is expected to witness significant growth in the coming years due to the increasing prevalence of genetic disorders and the rising demand for innovative treatment options. The development of advanced technologies, such as genome editing and gene silencing, is expected to further drive the growth of the market. Additionally, the increasing focus on precision medicine and personalized treatment options is likely to create lucrative opportunities for the market players.

Furthermore, the increasing investments in research and development activities, coupled with the growing number of clinical trials, are expected to fuel the growth of the market. The adoption of advanced healthcare infrastructure and the increasing demand for better healthcare services in emerging economies are expected to further contribute to the growth of the market.

Adeno-Associated Virus Vector-Based Gene Therapy Market Segmentations

The market can be categorised into therapeutic agents, indication type, and treatment channel.

Market Breakup by Therapeutic Agents

  • Corticosteroid Drugs
  • Immunosuppressive Drugs
  • ACE Inhibitors and ARBs
  • Others

Market Breakup by Indication Type

Haematological Disorders

  • Haemophilia A
  • Haemophilia B

Ophthalmological Disorders

  • Chloridaemia
  • Retinitis Pigmentosa

Lysosomal Storage Disorders

  • Fabry Disease
  • Pompe Disease
  • Hunter Syndrome

Neurological Disorders

  • Parkinson's Disease
  • Batten Disease

Musculoskeletal Disorders

  • Duchenne Muscular Dystrophy (DMD)
  • Spinal Muscular Atrophy (SMA)

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Adeno-Associated Virus Vector-Based Gene Therapy Market Scenario

The global adeno -Associated Virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031. North America dominates the market, followed by Europe and Asia Pacific. The high prevalence of genetic disorders in North America, coupled with the favorable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for AAV vector-based gene therapy, with the presence of key players and increasing investments in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of genetic disorders and rising healthcare expenditure in the region.

Key Players in the Global Adeno-Associated Virus Vector-Based Gene Therapy Market

The report gives an in-depth analysis of the key players involved in the adeno-associated virus vector-based gene therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Arya Sciences Acquisition Corp
  • Pfizer Inc
  • Roche Holding AG
  • BioMarin Pharmaceutical Inc
  • Bayer AG
  • Coave Therapeutics
  • MeiraGTx Limited
  • Neurocrine Biosciences, Inc
  • Biogen, Inc
  • Sangamo Therapeutics
  • Sarepta Therapeutics, Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology3 Executive Summary
4 Adeno-Associated Virus Vector-Based Gene Therapy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Adeno-Associated Virus Vector-Based Gene Therapy Market
8.1 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Overview
8.2 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Historical Value (2016-2022)
8.2.1.2 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Forecast Value (2023-2031)
8.3 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Therapeutic Agents
8.3.1 Market Overview
8.3.1.1 Corticosteroid Drugs
8.3.1.2 Immunosuppressive Drugs
8.3.1.3 ACE Inhibitors and ARBs
8.3.1.4 Others
8.4 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Indication Type
8.4.1 Market Overview
8.4.1.1 Hematological Disorders
8.4.1.1.1 Hemophilia A
8.4.1.1.2 Hemophilia B
8.4.1.2 Ophthalmological Disorders
8.4.1.2.1 Choroideremia
8.4.1.2.2 Retinitis Pigmentosa
8.4.1.3 Lysosomal Storage Disorders
8.4.1.3.1 Fabry Disease
8.4.1.3.2 Pompe Disease
8.4.1.3.3 Hunter Syndrome
8.4.1.4 Neurological Disorders
8.4.1.4.1 Parkinson's Disease
8.4.1.4.2 Batten Disease
8.4.1.5 Musculoskeletal Disorders
8.4.1.5.1 Duchenne Muscular Dystrophy (DMD)
8.4.1.5.2 Spinal Muscular Atrophy (SMA)
8.5 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Treatment Channel
8.5.1 Market Overview
8.5.1.1 Public
8.5.1.2 Private
8.6 Global Adeno-Associated Virus Vector-Based Gene Therapy Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Middle East and Africa
8.6.1.5 Latin America
9 North America Adeno-Associated Virus Vector-Based Gene Therapy Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Adeno-Associated Virus Vector-Based Gene Therapy Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Adeno-Associated Virus Vector-Based Gene Therapy Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Adeno-Associated Virus Vector-Based Gene Therapy Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Adeno-Associated Virus Vector-Based Gene Therapy Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Arya Sciences Acquisition Corp.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Pfizer Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Roche Holding AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 BioMarin Pharmaceutical Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Bayer AG
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Coave Therapeutics
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 MeiraGTx Limited
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Neurocrine Biosciences, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Biogen, Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Sangamo Therapeutics
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Sarepta Therapeutics, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Global Adeno-Associated Virus Vector-Based Gene Therapy Market Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Companies Mentioned

  • Arya Sciences Acquisition Corp.
  • Pfizer Inc.
  • Roche Holding AG
  • BioMarin Pharmaceutical Inc.
  • Bayer AG
  • Coave Therapeutics
  • MeiraGTx Limited
  • Neurocrine Biosciences, Inc.
  • Biogen, Inc.
  • Sangamo Therapeutics
  • Sarepta Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information